Chemomab Therapeutics earnings were -$7.6M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest CMMB earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$2.2M, up 22.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CMMB reported annual earnings of -$9.0M, with -35.5% growth. The next CMMB earnings date is Sep 17, 2026.
Chemomab Therapeutics Earnings Reports & History FAQ
What were Chemomab Therapeutics's earnings last quarter?
On CMMB's earnings call on Sep 17, 2026, Chemomab Therapeutics (NASDAQ: CMMB) reported Q2 2026 earnings per share (EPS) of -$0.24, up 25% year over year. Total CMMB earnings for the quarter were -$2.17 million. In the same quarter last year, Chemomab Therapeutics's earnings per share (EPS) was -$0.32.
The next CMMB earnings date is Sep 17, 2026. Add CMMB to your watchlist to be reminded of Chemomab Therapeutics's next earnings date.
Is Chemomab Therapeutics profitable or losing money?
As of the last Chemomab Therapeutics earnings report, Chemomab Therapeutics is currently losing money. Chemomab Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$7.55 million, a 36.13% decrease year over year.
What was CMMB's earnings growth in the past year?
As of Chemomab Therapeutics's earnings date in Sep 17, 2026, Chemomab Therapeutics's earnings has grown year over year. CMMB earnings in the past year totalled -$7.55 million.
What are Chemomab Therapeutics's earnings expectations?
The current EPS estimate for Chemomab Therapeutics's earnings report in Sep 17, 2026 is $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.